Anixa Biosciences, Inc. (ANIX)
2.99
+0.21
(+7.55%)
USD |
NASDAQ |
Oct 23, 16:00
2.97
-0.02
(-0.67%)
After-Hours: 20:00
Anixa Biosciences Enterprise Value : 88.45M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 88.45M |
| October 22, 2026 | 81.18M |
| October 21, 2026 | 78.76M |
| October 20, 2026 | 77.73M |
| October 19, 2026 | 75.31M |
| October 16, 2026 | 77.38M |
| October 15, 2026 | 81.18M |
| October 14, 2026 | 76.86M |
| October 13, 2026 | 77.38M |
| October 12, 2026 | 83.26M |
| October 09, 2026 | 85.34M |
| October 08, 2026 | 85.68M |
| October 07, 2026 | 87.06M |
| October 06, 2026 | 89.49M |
| October 05, 2026 | 87.06M |
| October 02, 2026 | 87.06M |
| October 01, 2026 | 80.84M |
| September 30, 2026 | 86.37M |
| September 29, 2026 | 83.61M |
| September 28, 2026 | 81.53M |
| September 25, 2026 | 81.18M |
| September 24, 2026 | 81.18M |
| September 23, 2026 | 80.15M |
| September 22, 2026 | 81.53M |
| September 21, 2026 | 78.42M |
| Date | Value |
|---|---|
| September 18, 2026 | 80.84M |
| September 17, 2026 | 80.49M |
| September 16, 2026 | 74.96M |
| September 15, 2026 | 78.07M |
| September 14, 2026 | 81.88M |
| September 11, 2026 | 80.49M |
| September 10, 2026 | 80.15M |
| September 09, 2026 | 82.91M |
| September 08, 2026 | 85.34M |
| September 04, 2026 | 91.21M |
| September 03, 2026 | 90.52M |
| September 02, 2026 | 93.29M |
| September 01, 2026 | 98.48M |
| August 31, 2026 | 100.90M |
| August 28, 2026 | 105.39M |
| August 27, 2026 | 109.54M |
| August 26, 2026 | 109.72M |
| August 25, 2026 | 111.62M |
| August 24, 2026 | 110.24M |
| August 21, 2026 | 113.35M |
| August 20, 2026 | 109.20M |
| August 19, 2026 | 113.35M |
| August 18, 2026 | 103.66M |
| August 17, 2026 | 105.74M |
| August 14, 2026 | 95.02M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Vicapsys Life Sciences, Inc. | 13.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.625M |
| Total Expenses (Quarterly) | 2.606M |
| EPS Diluted (Quarterly) | -0.0762 |
| Earnings Yield | -10.36% |
| Normalized Earnings Yield | -10.36 |